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Summary
Background: This randomised study was designed to deter-
mine the response rate, survival and toxicity of single-agent
gemcitabine and cisplatin-etoposide in chemo-naive patients
with locally advanced or metastatic non-small-cell lung cancer.
Patients and methods: Gemcitabine 1,000 mg/m2 was given
as a 30 min intravenous infusion on days 1, 8, 15 of a 28-day
cycle, cisplatin 100 mg/m2 on day 1, and etoposide 100 mg/m2
on days 1 (following cisplatin), 2 and 3. Major eligibility
criteria included histologically confirmed non-small-cell lung
cancer, measurable disease, Zubrod PS 0-2; no prior chemo-
therapy, no prior radiation of the measured lesion, and no
CNS metastases.
Results: 146 patients were enrolled, 71 patients on gemcita-
bine and 75 patients on cisplatin-etoposide. Patient character-
istics were well matched across both arms. Sixty-six gemcita-
bine patients and 72 cisplatin-etoposide patients were evalu-
able. Partial responses were seen in 12 gemcitabine patients
(18.2%; 95% CI: 9.8-30) and 11 cisplatin-etoposide patients
(15.3%; 95% CI: 7.9-25.7). Early indications show no statistical
differences between the two treatments with respect to time to
disease progression or survival. Haematological and labora-
tory toxicity were moderate and manageable. However, hos-
pitalisation because of neutropenic fever was required for 6
(8%) cisplatin-etoposide patients but not for any gemcitabine
patients. Non-haematological toxicity was more pronounced
with significant differences in nausea and vomiting (grade 3
and 4: 11% gemcitabine vs. 29% cisplatin-etoposide; despite
the allowance for 5-HT3 antiemetics during the first cycle of
cisplatin-etoposide), and alopecia (grade 3 and 4: 3% gemcita-
bine vs. 62% cisplatin-etoposide).
Conclusions: In this randomised study, single-agent gem-
citabine was at least as active but better tolerated than the
combination cisplatin-etoposide.
Key words: cisplatin, etoposide, gemcitabine, non-small-cell
lung cancer, randomised phase II study
Introduction
The systemic treatment currently recommended in
patients with advanced non-small-cell lung cancer
(NSCLC) is cisplatin-based combination chemotherapy
[1]. However, because of the toxicity of cisplatin, combi-
nation treatment can only be administered to patients in
good general health, which is the case only for a minor-
ity of stage IV patients. Gemcitabine is a new nucleoside
analogue with major antitumour efficacy in various solid
tumours in contrast to cytosine-arabinoside which is not
active in solid tumours. Over the last few years a num-
ber of phase II studies have been undertaken with
gemcitabine as a single agent [2-5] and in combination
[6, 7] in patients with NSCLC. The schedule currently
recommended for gemcitabine is a 1,000 mg/m2 30-
minute intravenous infusion given on days 1, 8 and 15 of
a 28-day cycle. Phase II studies with gemcitabine in the
first-line treatment of advanced NSCLC have produced
consistent response rates of 20% with a median survival
of 38 weeks [2-5]. In addition to its objective antitumour
activity, gemcitabine is one of the first drugs with docu-
mented data on symptom benefit. Several phase II stud-
ies have also shown that gemcitabine is well tolerated, is
easy to administer on an outpatient basis, and is effec-
tive in non-small-cell lung cancer, with activity in a
range that can be expected for cisplatin-containing
combination regimens. Gemcitabine can be particularly
beneficial for the therapy of elderly and unfit patients as
well as for the palliation of tumour-related symptoms
[8]. It therefore seemed logical to compare gemcitabine
as a single agent with a standard combination chemo-
therapy (such as cisplatin-etoposide) to establish whether
better tolerated treatment could be given to patients who
could not receive cisplatin-containing chemotherapy
because of its toxicity.
526
Patients and methods
Major eligibility criteria
Patients were included in the study only if they met the following
criteria: histological diagnosis of NSCLC, stage Ilia (if inoperable),
Illb, or IV, according to the American Joint Committee of Cancer
(AJCC); no prior chemotherapy; no prior radiation therapy except
where the irradiated area was not the only source of measurable
disease; performance status of $ 2 on the Zubrod scale; adequate
bone marrow reserve (white blood cell count > 3.5 x 1O9/1, platelets
5= 100 x 109/l, haemoglobin 3> 100 g/1, age ^ 18 years. Patients were
excluded from the study if they had central nervous system metastases,
bilirubin >1.5 times normal, prothombin time or activated partial
thromboplastin time > 1 5 times control, ALT or AST > 3 times
normal (or up to 5 times normal in patients with known liver metas-
tases), serum calcium levels above the normal limits, pregnancy, breast
feeding, serious concomitant systemic disorders, or concomitant treat-
ment with nephrotoxic antibiotics.
Treatment
Patients were randomised to receive either gemcitabine or cisplatin-
etoposide. Gemcitabine 1,000 mg/m2 was given as a 30-minute intra-
venous infusion on days 1, 8 and 15 of a 28-day cycle. Cisplatin 100 mg/
m2 was given intravenously on day 1 of the 28-day cycle, and etoposide
100 mg/m2 was administered intravenously on day 1 (following cis-
platin), 2 and 3 of each 28-day cycle. Patients could remain in the study
for up to six cycles or until disease progression was noted.
Study design
This was an open label randomised trial carried out with ethical
committee approval. Patients were stratified according to stage, per-
formance status and investigator centre using the algorithm outlined
by Pocock and Simon [9].
Concomitant therapy
Patients were allowed to take medication for other illnesses provided
this was documented. Colony stimulating factors were also allowed for
prolonged myelosuppression, i.e., lasting five days or more (in fact no
patient experienced such prolonged myelosuppression and no patients
received growth factors). Prednisone 10 mg/m2 was permitted for other
diseases. In the cisplatin-etoposide arm, prophylactic 5-HT3 receptor
blocking agents and steroids (dexamethasone 20 mg or equivalent)
were permissible. In the gemcitabine arm, prophylactic 5-HT3 anti-
emetics were not permitted at dose 1 cycle 1 but were allowed at
subsequent doses depending on the severity of nausea and vomiting
following the first dose. Patients with disease progression requiring
other forms of specific antitumour therapy were removed from this
study. If an existing lesion became more painful and was not accom-
panied by other objective changes indicating disease progression,
palliative local radiotherapy was permitted without discontinuing the
patient, provided other measurable sites were being assessed.
Discontinuations
Patients were discontinued from the study under the following circum-
stances: if there was evidence of progressive disease; if the attending
physician thought the change of therapy was in the best interest of the
patient; if the patient requested a discontinuation; if the patient
experienced unacceptable drug toxicity; if the patient's best response
was achieved; if chemotherapy could not be administered to the
patient within four weeks from the time of the last treatment. Time to
treatment failure was measured from the time of first dose of the study
drug(s) to discontinuation. Patients were kept on study for up to six
cycles.
Qualification for analysis
All patients who received at least one dose of gemcitabine or cisplatin-
etoposide were evaluated for safety. All patients randomised to treat-
ment and meeting the eligibility criteria were considered qualified for
objective tumour response assessment (using standard WHO response
criteria) and for analysis of the time to event parameters. In addition,
an intent-to-treat analysis of all randomised patients was made
Dose adjustments (see Table 1) within a cycle were based on weekly
absolute granulocyte and platelet counts, taken on the day of therapy
Serum creatinine was obtained prior to each cycle in order to deter-
mine calculated creatinine clearance and ongoing clinical assessment
of non-haematological toxicities.
Results
Between June and December 1995, 146 patients were
enrolled, 71 patients in the gemcitabine arm, and 75
patients in the cisplatin-etoposide arm. For this early
analysis, information was collected as of July first 1996
(all patients off trial). The data are therefore fully mature
with respect to response rate but not for time to event
(i.e., disease progression and survival). Patient demo-
graphics and baseline disease characteristics were well
matched across treatment arms (Table 2) with slightly
more cases of Zubrod performance status grade 2 in the
gemcitabine arm, and slightly more stage Ilia disease in
a cisplatin-etoposide arm. The median age in both treat-
ment groups was 59 years. In the gemcitabine and cispla-
tin-etoposide groups there were, respectively, 29 and 28
female patients, 37 and 31 patients with adenocarcinoma,
and 22 and 24 patients with squamous cell carcinoma.
Treatment
The number of cycles completed by patients ranged
from one to six on both treatment arms. The median
Table I. Dose reductions and omissions made in the event of toxicity.
Toxicity
Granulocytes Platelets
(x 1O9/I) (x 109/l)
1000-1500 75.0-99.9
500-999 50.0-74.9
<500 <50.0
Creatinine clearance (ml/min)
40-60
<40
Non-haematological (first cycle)
WHO grade 31
WHO grade 4
Non-haematological (subsequent cycles)
WHO grade 3 '
WHO grade 4
% full
dose
gemci-
tabine
75
50
Omit
100
100
50 or
omit
Omit
75
50 or
omit
% full
dose
etopo-
side
50
Omit
Omit
100
100
100
100
100
100
% full
dose
cispla-
tin
50
Omit
Omit
75
Omit
100
100
100
100
Except nausea/vomiting or alopecia.
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Table 2. Characteristics of enrolled patients. Table 3. Efficacy.
Patients GEM C/E
71 75
Age (yrs)
Median
Range
Sex
Female
Male
Zubrod PS
0
1
2
Stage
IIIA
IIIB
IV
Histology
Adenocarcinoma
Squamous
Other
59
32-80
29
42
16
43
12
4
13
54
37
22
12
59
33-78
28
47
17
51
7
6
13
56
31
24
20
(and mean) number of cycles received per patient was
2.0 (3.0) for gemcitabine and 3.0 (3.0) for cisplatin-
etoposide. Overall, 99% of the protocol-defined injec-
tions were administered in both arms with 93% and 95%
respectively given at the assigned doses. Dose reductions
were not common, 6% with gemcitabine and 4% with
cisplatin-etoposide. The mean dose intensities were:
gemcitabine 967 mg/m2 (days 1, 8 and 15 of a 28 day
cycle), cisplatin 97 mg/m2 (day 1), and etoposide 99 mg/
m2 (days 1, 2 and 3).
Efficacy
Sixty-six (93%) gemcitabine patients and 72 (96%) cis-
platin-etoposide patients were evaluable for efficacy.
Five gemcitabine patients (7%) were not evaluable for
efficacy (2 patients with rapid disease progression, three
patients with no bidimensionally measurable lesions).
Three cisplatin-etoposide patients (4%) were not evalu-
able for efficacy (2 patients with rapid disease progres-
sion, one patient with no bidimensionally measurable
lesions). Efficacy data are shown in Table 3. With gem-
citabine, 12 patients had a partial response for an overall
response rate of 18.2% (95% CI: 9.8%-30%). With cis-
platin-etoposide, 11 patients had a partial response for
an overall response rate of 15.3% (95% CI: 7.9%-25.7%).
At the time of data cut-off, there were no statistical
differences between the two treatment arms with respect
to time and progression and survival (Table 3).
Toxicity profile
Haematological toxicity was not a clinical problem in
either treatment arm (Table 4). Normal platelet levels
were reported for 87% of gemcitabine patients and 94%
of cisplatin-etoposide patients. Two patients experienced
grade 3 toxicity with gemcitabine but no patient showed
grade 4 toxicity. There was no need for platelet trans-
GEM
n (%)
C/E
n (%)
Partial response
95% CI
Stable disease
Time to progression
Median"
95% CI
Survival
Median11
95% CI
12(18.2)
(9.8-30)
30 (45 5)
4.2 mo
(2 9-5.6)
11(15.3)
(7.9-25.7)
35 (48.6)
4.9 mo
(3.2-5.8)
P >0.90
6.6 mo
(4.9-7.1)
7.6 mo
(5.6-9 6)
P > 0.90
" Patients progression free: 35% for GEM; 38% for C/E.
b
 Patients still alive: 50% for GEM; 46% for C/E.
Table 4. Toxicity profile.
Maximum WHO grades (%)
Haematological
Neutrophils
Haemoglobin
Platelets
Liver
Alk Phos
ALT
AST
Renal
Bilirubin
BUN
Symptomatic
Hair
Nausea/vomiting
Neurohearing
Dyspnoea
GEM
C/E
GEM
C/E
GEM
C/E
GEM
C/E
GEM
C/E
GEM
C/E
GEM
C/E
GEM
C/E
GEM
C/E
GEM
C/E
GEM
C/E
GEM
C/E
0
70
73
43
34
87
94
72
87
70
91
77
95
98
100
93
95
97
0
45
11
98
84
76
81
3
6
3
4
3
2
0
1.6
0
0
0
0
0
0
0
0
0
3
60
11
25
0
6
4
4
4
2
12
0
0
0
0
0
1.6
0
0
0
0
0
0
0
0
0
2
0
4
0
0
6
0
fusions. Anaemia was usually mild. Grade 3 haemo-
globin toxicity was seen in 4% of gemcitabine patients
and 3% of cisplatin-etoposide patients, but no grade 4
toxicity was seen in either group. However, red cell
transfusions were given to nine gemcitabine patients
and to 17 cisplatin-etoposide patients. A normal neutro-
phil count was reported in 70% of gemcitabine patients,
and in 73% of cisplatin-etoposide patients. Grade 3 and
4 toxicity was seen in 6% and 2% of gemcitabine patients
and in 3% and 12% of cisplatin-etoposide patients.
Hospitalisation because of neutropenic fever was re-
quired for 6 (8%) cisplatin-etoposide patients but was
not necessary for any gemcitabine patients.
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Laboratory toxicity was clinically insignificant (Table
4). The incidence of alopecia was minimal with gemcita-
bine (97% of patients had no hair loss (Table 4), whereas
60% and 2% of cisplatin-etoposide patients had grade 3
and 4 hair loss. The majority of cisplatin-etoposide
patients reported nausea and vomiting with about 30%
grade 3 and 4 toxicity; only 11% of cisplatin-etoposide
patients experienced no nausea and vomiting. With
gemcitabine, grade 3 nausea and vomiting was only 11%
with no grade 4 toxicity; as many as 45% of the patients
had no nausea and vomiting. Neuro-hearing toxicity was
greater with cisplatin-etoposide than with gemcitabine.
Grade 3 pulmonary toxicity (dyspnoea at rest) was
seen in three patients in each treatment arm. Grade 4
pulmonary toxicity (dyspnoea requiring bed rest) was
experienced in four patients on gemcitabine. Drug
causality could not be excluded for two patients in each
treatment arm. For five of the seven patients in the
gemcitabine arm dyspnoea was attributed to the pri-
mary lung cancer.
Discussion
The results achieved by chemotherapy in advanced,
non-small-cell lung cancer continue to be unsatisfactory
and are largely palliative in nature. Cisplatin-based
combination therapy is currently the standard recom-
mended treatment [10]. This recommendation is based
upon the higher response rates and the slightly improved
survival benefit, small in extent but statistically sig-
nificant, which can be attributed to this combination
therapy when compared with single-agent therapy. For
example, the combination cisplatin-etoposide produces
response rates of 11%—30% [11, 12] and a median survival
of 16-42 weeks, with a pooled median survival of 27
weeks [10, 13-18]. In 1989 an ECOG study showed that
single-agent carboplatin produced a response rate of 9%
and a median survival of 30 weeks [19]. Although count-
less studies have demonstrated that the inclusion of
platinum agents in combination chemotherapy produces
better results than early combinations without cisplatin,
the use of chemotherapy for the cytostatic therapy of
advanced NSCLC has not increased appreciably over
the last 15 years and remains comparatively low [20]. In
the UK, only about 20% of the patients with stage IV
NSCLC are treated with chemotherapy. The reason for
the low acceptance of chemotherapy may be that the
current standard combinations are considered to be too
toxic to be used beneficially in older and polymorbid
patients. The perception in the majority of clinicians is
that the quality of a shorter life without combination
chemotherapy is more worthwhile than a longer life but
one in which patients suffer greater side effects.
In this respect the concept of single-agent therapy
appears to be an attractive alternative when the ultimate
goal of palliation can be similarly achieved by a less
toxic chemotherapy with increased practicability, i.e.,
the possibility of outpatient administration. Random-
ised studies have shown that combination therapy is
usually statistically superior to single-agent therapy, not
only in response rates but also in life expectancy [19, 21-
29]. However, in the earlier studies no systematic
attempt was made to assess the effect of chemotherapy
on the patient's quality of life.
We initiated a randomised study to compare gemci-
tabine with cisplatin-etoposide in order to determine
whether single-agent gemcitabine would prove as effec-
tive as established combination chemotherapy. At the
same time we were interested to see whether gemcitabine
would be better tolerated, so that it could be used in
patients in which cisplatin-based chemotherapy would
be too toxic.
The single-agent response rate for gemcitabine
(18.2%) in this randomised study is comparable to
that seen with the other newer agents (vinorelbine, the
taxanes and camptothecans), and is promising given the
acceptable toxicity profile of gemcitabine. In this ran-
domised setting we have shown that single-agent gem-
citabine is indeed as effective as the traditionally recom-
mended combination of cisplatin-etoposide. Because of
the short duration of the ensuing follow-up, it is not yet
possible to provide accurate time to progression or
median survival data. However, to date no great differ-
ences have been seen, with the median survival currently
at 6.6 months for gemcitabine versus 7.6 months for
cisplatin-etoposide (P > 0.90).
Non-haematological toxicity was significantly better
in gemcitabine patients than in cisplatin-etoposide pa-
tients. The incidence and intensity of nausea and vom-
iting was negligible with gemcitabine, with nothing
reported over grade 3. By contrast, more than half of
the cisplatin-etoposide patients reported grade 3 and 4
toxicity, despite the fact that 5-HT3 receptor blocking
agents and steroids were given prophylactically with the
first cisplatin-etoposide dose. In the gemcitabine arm
no such prophylactic drugs were permitted for the first
dose, although they were allowed for subsequent doses if
the patients experienced nausea or vomiting following
the first administration. Similarly, alopecia was minimal
with gemcitabine whereas the majority of cisplatin-
etoposide patients experienced grade 3/4 alopecia.
Some studies have shown that patients treated with
gemcitabine can develop pulmonary difficulties [30]. In
our study the majority of patients did not experience
pulmonary toxicity.
Haematological toxicity was more pronounced
with cisplatin-etoposide compared with gemcitabine.
Anaemia was usually mild in both treatment arms,
although red cell transfusions had to be administered to
twice as many cisplatin-etoposide patients (compared
with gemcitabine). Furthermore, there was no neutro-
penic fever or sepsis with gemcitabine whereas 8% of
patients on cisplatin-etoposide had to be hospitalised
for neutropenic sepsis. Thrombocytopenia was generally
mild in both treatment arms, although in the cisplatin-
etoposide arm, one haemorrhage did occur and several
platelet transfusions were required.
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In conclusion, we believe that this randomised study
provides strong supporting evidence for the efficacy
of gemcitabine in NSCLC. Single-agent gemcitabine
appears to be as active but at the same time much less
toxic than the combination cisplatin-etoposide in the
first-line chemotherapy of advanced NSCLC. With less
toxic anticancer drugs like gemcitabine, the physician
now has greater choice in choosing treatment. In pa-
tients where quality of life is particularly important and
patients are unable to tolerate the toxicities of tradi-
tional cisplatin-based chemotherapy, gemcitabine offers
lower toxicity yet activity which is equivalent to that of
other single agents. On the other hand, where physicians
want to aim for higher response rates and treat more
intensively they can use a combination chemotherapy
using cisplatin or one or more of the newer agents (e.g.,
vinorelbine, gemcitabine, taxanes, camptothecans).
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